Program: Monday (28.10.2024)

Name: Scientific Session: Special Situations & Cases
Start: 2024-10-28T08:00
End: 2024-10-28T09:00
Location: Großer Saal

08:00 – 09:00

Room: Großer Saal

Scientific Session Special Situations & Cases

Alexander Fosså
Anna Sureda

Treatment Approaches in Ressource Constraint Settings
- Chite Asirwa
- Otavio Baiocchi
HL Richter Transformation Pathologists perspective
- Sylvia Hartmann
HL Richter Transformation HL perspective
- Mark Hertzberg
HL Richter Transformation CLL perspective
- Othman Al-Sawaf

09:15 – 10:15

Room: Großer Saal

Scientific Session NLPHL

Richard Hoppe
Wolfram Klapper

09:15–09:35
NLPHL: HL, NHL or something else?
- Sylvia Hartmann
09:35–09:55
First-line treatment of NLPHL with HL-directed approaches
- Dennis Eichenauer
09:55–10:15
Treatment of NLPHL with NHL-directed approaches
- Graham Collins
10:15–10:20
Q&A
- Graham Collins
- Dennis Eichenauer
- Sylvia Hartmann

10:30 – 12:00

Room: Großer Saal

Scientific Session Living Beyond Lymphoma

John Radford
Flora van Leeuwen

10:30–10:50
Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)
- Stephen Ansell
10:50–11:10
Starting Living beyond Lymphoma with HL diagnosis
- Karolin Behringer
- Maximilian Büttner
11:10–11:30
Participation in and (cost-)effectiveness of the Dutch HL survivorship care program
- Berthe Aleman
- Annelies Nijdam
11:30–11:40
- Abstract Talk
A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations
- Michael Oertel
11:40–11:50
- Abstract Talk
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
- Sidsel Juul
11:50–12:00
- Abstract Talk
Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors
- Zeinab Salah Seliem

12:30 – 14:00

Room: Großer Saal

Scientific Session Relapsed & Refractory HL

Philippe Armand
Craig H. Moskowitz

12:30–12:50
Updated approach to second-line treatment
- Alison Moskowitz
12:50–13:10
Emerging strategies to overcome anti-PD1 resistance
- Stephen Ansell
13:10–13:30
Implementing raditoherapeutic concepts in rrHL care
- Christian Baues
13:30–13:40
- Abstract Talk
Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.
- Anna Sureda
13:40–13:50
- Abstract Talk
Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients
- Francesco Corrado
13:50–14:00
- Abstract Talk
Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
- Alison Moskowitz

14:00

Room: Großer Saal

Main Program Closing remarks

Ranjana Advani
Sally Barrington
Sven Borchmann
Carsten Kobe
Wouter Plattel

14:00–14:25
Workshop Report
- Sally Barrington
- Sven Borchmann
- Carsten Kobe
- Wouter Plattel
- Davide Rossi
14:25–14:45
Best of ISHL13
- Ranjana Advani
Farewell
- Peter Borchmann

Program: Monday (28.10.2024)

08:00 – 09:00

Scientific Session Special Situations & Cases

Treatment Approaches in Ressource Constraint Settings

HL Richter Transformation Pathologists perspective

HL Richter Transformation HL perspective

HL Richter Transformation CLL perspective

09:15 – 10:15

Scientific Session NLPHL

NLPHL: HL, NHL or something else?

First-line treatment of NLPHL with HL-directed approaches

Treatment of NLPHL with NHL-directed approaches

Q&A

10:30 – 12:00

Scientific Session Living Beyond Lymphoma

Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

Starting Living beyond Lymphoma with HL diagnosis

Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

12:30 – 14:00

Scientific Session Relapsed & Refractory HL

Updated approach to second-line treatment

Emerging strategies to overcome anti-PD1 resistance

Implementing raditoherapeutic concepts in rrHL care

Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

14:00

Main Program Closing remarks

Workshop Report

Best of ISHL13

Farewell

Archive